Racial Disparities in Systemic Sclerosis: Short‐ and Long‐Term Outcomes Among African American Participants of SLS I and II

Схожие документы

• Reliability and Minimal Clinically Important Differences of FVC. Results from the Scleroderma Lung Studies (SLS-I and SLS-II)
  по: Kafaja, Suzanne, et al.
  Опубликовано: (2018)
• The MUC5B Promoter Variant does not Predict Progression of Interstitial Lung Disease in Systemic Sclerosis
  по: Volkmann, Elizabeth R., et al.
  Опубликовано: (2020)
• Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II)
  по: Khanna, Dinesh, et al.
  Опубликовано: (2019)
• Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease
  по: Volkmann, Elizabeth R., et al.
  Опубликовано: (2016)
• Pneumoproteins KL-6 and CCL-18 Predict Progression of Interstitial Lung Disease in Systemic Sclerosis
  по: Volkmann, Elizabeth R., et al.
  Опубликовано: (2019)